Top Markets
Coin of the day
Aceragen, Inc. Aceragen, Inc.

Aceragen, Inc.

ACGN
Ранг среди акций #39037
Aceragen, Inc., a biopharmaceutical firm in its clinical development phase,... Aceragen, Inc., a biopharmaceutical firm in its clinical development phase, operates out of Exton, Pennsylvania, and was founded in 1989. The company, which transitioned from Idera Pharmaceuticals, Inc. and adopted its current name in January 2023, concentrates on the discovery, advancement, and bringing to market of therapeutic agents for uncommon lung and autoimmune conditions exclusively within the United States. Its product development pipeline includes ACG-701, currently undergoing Phase 2 clinical evaluation for both cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801, which is being developed to address Farber disease. Moreover, Aceragen maintains a partnership and option agreement with Scriptr Global, Inc. This collaboration aims to pinpoint, research, and cultivate gene therapy options intended for the management, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
Цена акции
$0.38
Последняя синхронизация: 2023-09-01
Рыночная капитализация
$677.16K
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
US
Торговля Aceragen, Inc. (ACGN)

Категория

EPS для Aceragen, Inc. (ACGN)
EPS по состоянию на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Aceragen, Inc., текущий EPS компании (TTM) составляет 0. В конце 2026 EPS компании составлял 0, равна показателю 2026 года, равному 0.
История EPS компании Aceragen, Inc. с 2026 по 2026
EPS на конец каждого года
Год EPS Изменить
Недостаточно данных для указанных дат.
EPS для аналогичных компаний или конкурентов
Компания EPS Разница в EPS Страна
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE